Daewoong Pharmaceutical CEO Park Sung-soo spoke at the GMP certification ceremony for the company's new stem cell plant in Indonesia, marking the 20th anniversary of its presence in the Indonesian market. The facility, operated by Daewoong Biologics Indonesia, a subsidiary of Daewoong Pharmaceutical, is set to collaborate with local pharmaceutical and biotech industries on large-scale research and development projects. It will produce various stem cell products, emphasizing its ability to deliver high-quality stem cells for Indonesian patients. The GMP certification ceremony, attended by 150 guests including Indonesian officials and South Korean representatives, highlighted Daewoong's commitment to integrating cutting-edge stem cell technology to enhance the quality of life in Indonesia. Having entered the Indonesian market in 2005, Daewoong plans to continue advancing the pharmaceutical and biotech sectors in Indonesia and nurturing local talent development, with a focus on research, development, and commercialization of treatments for intractable diseases and bioregenerative medicine.